These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 29301371)

  • 1. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice.
    Wang D; Luo Y; Wang X; Orlicky DJ; Myakala K; Yang P; Levi M
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model.
    Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak L; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2021-2033. PubMed ID: 29572114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats.
    Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak LO; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
    Diabetes Obes Metab; 2018 Nov; 20(11):2617-2626. PubMed ID: 29923295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes.
    Tang L; Wu Y; Tian M; Sjöström CD; Johansson U; Peng XR; Smith DM; Huang Y
    Am J Physiol Endocrinol Metab; 2017 Nov; 313(5):E563-E576. PubMed ID: 28811292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dapagliflozin ameliorates pancreatic injury and activates kidney autophagy by modulating the AMPK/mTOR signaling pathway in obese rats.
    Jaikumkao K; Promsan S; Thongnak L; Swe MT; Tapanya M; Htun KT; Kothan S; Intachai N; Lungkaphin A
    J Cell Physiol; 2021 Sep; 236(9):6424-6440. PubMed ID: 33559163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin attenuates fat accumulation and insulin resistance in obese mice with polycystic ovary syndrome.
    Lin B; Guo X; Lu W; Niu R; Zeng X; Chen Z; Wu C; Liu C
    Eur J Pharmacol; 2024 Aug; 977():176742. PubMed ID: 38880216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
    Terami N; Ogawa D; Tachibana H; Hatanaka T; Wada J; Nakatsuka A; Eguchi J; Horiguchi CS; Nishii N; Yamada H; Takei K; Makino H
    PLoS One; 2014; 9(6):e100777. PubMed ID: 24960177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.
    Sa-Nguanmoo P; Tanajak P; Kerdphoo S; Jaiwongkam T; Pratchayasakul W; Chattipakorn N; Chattipakorn SC
    Toxicol Appl Pharmacol; 2017 Oct; 333():43-50. PubMed ID: 28807765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats.
    Swe MT; Thongnak L; Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Lungkaphin A
    Clin Sci (Lond); 2019 Dec; 133(23):2415-2430. PubMed ID: 31769484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
    Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice.
    Han T; Fan Y; Gao J; Fatima M; Zhang Y; Ding Y; Bai L; Wang C
    Adipocyte; 2021 Dec; 10(1):446-455. PubMed ID: 34550043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
    Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
    PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury.
    Chang YK; Choi H; Jeong JY; Na KR; Lee KW; Lim BJ; Choi DE
    PLoS One; 2016; 11(7):e0158810. PubMed ID: 27391020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
    Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH
    PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats.
    Devenny JJ; Godonis HE; Harvey SJ; Rooney S; Cullen MJ; Pelleymounter MA
    Obesity (Silver Spring); 2012 Aug; 20(8):1645-52. PubMed ID: 22402735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus.
    Kohlmorgen C; Gerfer S; Feldmann K; Twarock S; Hartwig S; Lehr S; Klier M; Krüger I; Helten C; Keul P; Kahl S; Polzin A; Elvers M; Flögel U; Kelm M; Levkau B; Roden M; Fischer JW; Grandoch M
    Diabetologia; 2021 Aug; 64(8):1834-1849. PubMed ID: 34131781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.
    Xu L; Nagata N; Nagashimada M; Zhuge F; Ni Y; Chen G; Mayoux E; Kaneko S; Ota T
    EBioMedicine; 2017 Jun; 20():137-149. PubMed ID: 28579299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Aso Y; Kato K; Sakurai S; Kishi H; Shimizu M; Jojima T; Iijima T; Maejima Y; Shimomura K; Usui I
    Int J Clin Pract; 2019 May; 73(5):e13335. PubMed ID: 30810254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin.
    Nørgaard SA; Briand F; Sand FW; Galsgaard ED; Søndergaard H; Sørensen DB; Sulpice T
    Eur J Pharmacol; 2019 Oct; 860():172537. PubMed ID: 31310751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.